Particularly in patients with high PD-L1 expression, the 5-year survival rate of immunotherapy can reach 40%.[38] However, despite the significant efficacy demonstrated by immunotherapy in the initial treatment phase, second-line treatment options after immunotherapy resistance and tumor progression remain limited. The gene discussed is CD274; the disease is neoplasm.